drugset / Trial / NCT07841301

PRF Versus Emdogain for Class II Furcation Defects of Mandibular Molars

NCT07841301 ↗

Completed 21 enrolled Medical University of Sofia
Non-randomizedParallel-groupSingle-blindTreatment

Summary

This study evaluated the regenerative potential of platelet-rich fibrin (PRF) compared with enamel matrix derivative (Emdogain®) in the surgical treatment of Class II (F2) furcation defects of mandibular molars. Twenty-one systemically healthy patients with a total of 30 mandibular molars presenting with buccal Class II furcation defects were included. The furcation defects were treated surgically with either PRF or Emdogain®. Clinical parameters, including periodontal probing depth, clinical attachment level, bleeding on probing, and furcation involvement, were assessed before treatment and during follow-up. Clinical and radiographic measurements of the furcation defects were also performed. The main follow-up evaluation was conducted 6 months after surgery. The study compared the clinical and radiographic outcomes of PRF and Emdogain® in the treatment of mandibular molars with Class II furcation defects.

Timeline

Start
2021-12-02
Primary completion
2023-05-29
Completion
2023-05-29

Drugs

EvaluationDrugModalityDoseRoute
Comparator Emdogain Other / unclassified — Topical
Subject Platelet rich fibrin Other / unclassified — Other

Indications